- Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b studyJun Guo
Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
BMC Cancer 13:136. 2013..This phase 1b study was designed to further evaluate the safety and efficacy of everolimus in VEGFr-TKI-refractory Chinese patients with mRCC...
- Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumorsBinghe Xu
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
J Hematol Oncol 4:3. 2011..This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics, safety, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advanced solid tumors...